Skip to main content

Table 1 Clinical studies of co-infusion of MSCs with HSCs for hematopoietic recovery after hematopoietic stem/progenitor cell transplantation

From: Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders

Number of patients

Median age of patients, years (range)

HSC donor

MSC donor

MSC dose (×106/kg)

Median time for Neut recovery (range)

Median time for Plt recovery (range)

Reference

46

44.5 (19–61)

HLA-matched sibling

HSC donor

1.0, 2.5, or 5.0

Neut >500/μl at day 14 (11–26)

Plt >20,000/μl at day 20 (15–36)

[26]

7

12 (1–44)

HLA-matched sibling in three cases

Unrelated donor in three cases

Cord blood in one case

HLA-matched sibling or HLA-haploidentical donor

1.0

Neut >500/μl at day 12 (10–28)

Plt >30,000/μl at day 12 (8–36)

[27]

8

7.5 (0.25–16)

Cord blood

HLA-haploidentical parent

0.9–5.0

Neut >500/μl at day 19 (9–28)

Plt >50,000/μl at day 53 (36–98)

[28]

  1. HLA human leukocyte antigen, HSC hematopoietic stem/progenitor cell, MSC mesenchymal stromal/stem cell, Neut neutrophil, Plt platelet